

Table of Contents

<u>Module 1 Administrative Information</u>	1
<u>Drug Establishment Registration Number</u>	1
<u>Statement of Commitment</u>	2
<u>US Agent Appointment Letter</u>	3
<u>Administrative Page</u>	4
<u>ADDRESSES</u>	5
<u>Module 2 Quality Overall Summary</u>	1
<u>2.3 Introduction</u> ¹	
<u>2.3.S.1 General Information</u> ²	
<u>2.3.S.2 Manufacture (*)</u> ³	
<u>2.3.S.3 Control of Drug Substance</u> ⁹	
<u>2.3.S.4 Reference Standards or Materials</u> ¹²	
<u>2.3.S.5 Container Closure System</u> ¹³	
<u>2.3.S.6 Stability</u> ¹⁴	
<u>Module 3 Quality</u>	1
<u>3.2.S.1 General Information</u> ¹	
<u>3.2.S.1.1 Nomenclature</u> ¹	
<u>3.2.S.1.2 Structure</u> ¹	
<u>3.2.S.1.3 General Properties</u> ¹	
<u>3.2.S.2 Manufacture</u> ¹	
<u>3.2.S.2.1 Manufacturer</u> ¹	
<u>3.2.S.2.2 Description of Manufacturing Process and Process Controls</u> ¹	
<u>3.2.S.2.3 Control of Materials (*)</u> ¹	
<u>3.2.S.2.4 Control of Critical Steps and Intermediates (*)</u> ¹	
<u>3.2.S.2.5 Process Validation and/or Evaluation (*)</u> ¹	
<u>3.2.S.2.6 Manufacturing Process Development (*)</u> ¹	
<u>3.2.S.3 Characterization</u> ¹	
<u>3.2.S.3.1 Elucidation of Structure and other Characteristics</u> ¹	
<u>3.2.S.3.2 Impurities</u> ¹	
<u>3.2.S.4 Control of Drug Substance</u> ¹	
<u>3.2.S.4.1 Specification</u> ¹	
<u>3.2.S.4.2 Analytical Procedures</u> ¹	
<u>3.2.S.4.3 Validation of Analytical Procedures</u> ¹	
<u>3.2.S.4.4 Batch Analysis</u> ¹	
<u>3.2.S.4.5 Justification of Specification</u> ¹	

3.2.S.5 Reference Standard or Materials¹

3.2.S.6 Container Closure System¹

3.2.S.7 Stability¹

3.2.S.7.1 Stability Summary and Conclusions¹

3.2.S.7.2 Post-approval Stability Protocol and Stability Commitment¹

3.2.S.7.3 Stability Data¹

3.2.R.1.S EXECUTED BATCH RECORDS (*)..... 1

**(*) – INFORMATION IS CONSIDERED CONFIDENTIAL AND IS NOT TO BE
DISCLOSED TO THE APPLICANTS.**

Module 1 Administrative Information

Table of contents

<u>Module 1 Administrative Information</u>	1
<u>Drug Establishment Registration Number</u>	1
<u>Statement of Commitment</u>	2
<u>US Agent Appointment Letter</u>	3
<u>Administrative Page</u>	4
<u>ADDRESSES</u>	5

Drug Establishment Registration Number

Module 2 Quality Overall Summary

Table of contents

<u>Module 2 Quality Overall Summary</u>	1
---	---

<u>2.3</u>	<u>Introduction</u>	1
------------	---------------------	---

<u>2.3.S.1</u>	<u>General Information</u>	2
----------------	----------------------------	---

<u>2.3.S.2</u>	<u>Manufacture (*)</u>	3
----------------	------------------------	---

<u>2.3.S.3</u>	<u>Control of Drug Substance</u>	9
----------------	----------------------------------	---

<u>2.3.S.4</u>	<u>Reference Standards or Materials</u>	12
----------------	---	----

<u>2.3.S.5</u>	<u>Container Closure System</u>	13
----------------	---------------------------------	----

<u>2.3.S.6</u>	<u>Stability</u>	14
----------------	------------------	----

(*) – INFORMATION IS CONSIDERED CONFIDENTIAL AND IS NOT TO BE DISCLOSED TO THE APPLICANTS.

2.%1 Introduction

Non-proprietary Name

Calcitriol

Proposed Indication

Used as a calcium regulator and an anti-psoriatic agent.

The proposed active drug substance has a non-proprietary name as Calcitriol. The active drug substance is manufactured at Formosa Laboratories with suitable quality to meet its intended use.